Commercial Benefits of Patient Engagement | DarshanTalks

Pharmacy Podcast Network - A podcast by Pharmacy Podcast Network

Categories:

In this episode of @darshantalks, we discuss Patient Centricity with guest Emma Sutcliffe. Emma Sutcliffe, Senior Vice President, Patient Insights and Solutions at Prime Global (https://primeglobalpeople.com/), talks about her experience hosting a webinar with two prominent industry leaders in the field of patient engagement. Novartis is the gold standard in patient engagement and was used as a case study in that session. Patient engagement is not yet mainstream, so experts are trying to push it towards the companies. Business benefits highly from patient engagement because of the "triple wing" concept: get medical services, products for patients in time and patient-focused drug development. Companies are 19% more likely to launch a drug with successful pharma if they've included patients within their clinical design program. It results in better medicines through the pipelines and patient activation. When patients become active, their patient activation measure (PAM) in patient-centred care is likely to rise on all four levels. They will be 28% more likely to consume fewer healthcare services, which means that the burden on ER departments will reduce as people are more health literate; they can manage health crises independently. Her company has started to help those patients who have reduced activation because of stress levels during a traumatic event, pandemic or work anxiety. Pharma companies that are adding to their PAM improve society's health activation as a whole. She compares UK and US healthcare and speaks about their merits. For the former, through the NHS, patients can try and circumvent diagnostic pathways to get treatments faster via patient activation. For the latter, it is that professional relationships between pharma companies and patient engagement groups are robust. Patients sometimes skirt around the rules and regulations to get access to medicines, but with patient engagement, they don't have to do that. She concludes with her observations on the present regional compliance challenges at play regarding pioneering global patient activation.  Learn more about your ad choices. Visit megaphone.fm/adchoices